Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
Previous Symbol
CUSIPN/A
Phone781-996-5252
Debt
Debt-to-Equity Ratio0.30
Current Ratio6.34
Quick Ratio6.27
Price-To-Earnings
Trailing P/E Ratio-0.94
Forward P/E Ratio-2.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales4,655.95
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.66 per share
Price / Book1.51
Profitability
EPS (Most Recent Fiscal Year)($5.84)
Net Income$-42,210,000.00
Net MarginsN/A
Return on Equity-72.11%
Return on Assets-52.71%
Miscellaneous
Employees37
Outstanding Shares33,800,000
Market Cap$193.31 million
OptionableOptionable
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals Inc (NASDAQ:KALA) announced its quarterly earnings results on Thursday, November, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.01. View Kala Pharmaceuticals' Earnings History.
When is Kala Pharmaceuticals' next earnings date?
What price target have analysts set for KALA?
4 equities research analysts have issued 12-month target prices for Kala Pharmaceuticals' shares. Their forecasts range from $15.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $25.75 in the next year. This suggests a possible upside of 367.3% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.
What is the consensus analysts' recommendation for Kala Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.
What are Wall Street analysts saying about Kala Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kala Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. " (10/11/2018)
- 2. HC Wainwright analysts commented, "Our 12-month target is derived from a market value of the firm at $1.1B, which includes a discounted cash flow-based asset value of $1.1B for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate." (9/10/2018)
Has Kala Pharmaceuticals been receiving favorable news coverage?
Media stories about KALA stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include AC Immune (ACIU), Lexicon Pharmaceuticals (LXRX), Y-mAbs Therapeutics (YMAB), Radius Health (RDUS), Aptinyx (APTX), Omeros (OMER), Principia Biopharma (PRNB), Inflarx (IFRX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), ProQR Therapeutics (PRQR), Eagle Pharmaceuticals (EGRX), CytomX Therapeutics (CTMX), Rocket Pharmaceuticals (RCKT) and ANI Pharmaceuticals (ANIP).
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 52)
- Mr. Todd Bazemore, Chief Operating Officer (Age 48)
- Dr. Kim Brazzell, Chief Medical Officer (Age 65)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CFO & Treasurer (Age 43)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Who are Kala Pharmaceuticals' major shareholders?
Kala Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.33%), Vanguard Group Inc. (1.51%), Vanguard Group Inc (1.51%), Wells Fargo & Company MN (1.21%), FMR LLC (0.96%) and Greylock Xii GP LLC (0.60%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Gregory Grunberg, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.
Which institutional investors are selling Kala Pharmaceuticals stock?
Which institutional investors are buying Kala Pharmaceuticals stock?
KALA stock was bought by a variety of institutional investors in the last quarter, including Greylock Xii GP LLC, BlackRock Inc., Dimensional Fund Advisors LP, Bridgeway Capital Management Inc., Wedbush Securities Inc., Renaissance Technologies LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Gregory Grunberg, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $5.51.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $193.31 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.
What is Kala Pharmaceuticals' official website?
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
